Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3 Randomized, Prospective, Double Blind, Within-Subject Vehicle Controlled, Multi-Center Study to Determine the Efficacy and Safety of Granexin® Gel in Reducing Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery

NCT04331080 is registered in ClinicalTrials.gov with Xequel Bio, Inc. as lead sponsor.

NCT NCT04331080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04331080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3 Randomized, Prospective, Double Blind, Within-Subject Vehicle Controlled, Multi-Center Study to Determine the Efficacy and Safety of Granexin® Gel in Reducing Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery
Lead sponsor
Xequel Bio, Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
July 1, 2020
Completion date
May 26, 2022
Enrollment
184 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

breast reconstruction, mammoplasty, scar, scarring